Why Novocure Stock Was so Healthy Today
In the biotech world, investors often heave a sigh of relief when an important clinical goal is met. Novocure announced that it has completed enrollment in its upcoming Panova-3 study of its Tumor Treating Fields product (TTFields). The clinical trial will gauge the efficacy of TTFields when administered in combination with chemotherapy treatments nabpaclitaxel and gemcitabine to fight locally advanced pancreatic cancer.